Key result
Antiplatelet agents such as aspirin and clopidogrel reduce ischemic events in primary and secondary stroke prevention, though more potent regimens increase bleeding complications.
Why the study?
What is the role of various antiplatelet agents and oral anticoagulants in the primary and secondary prevention of stroke across different patient populations?
Population
Patients at risk of stroke, patients with acute ischemic stroke, patients requiring secondary stroke…
Comparison
Antiplatelet agents and oral anticoagulants vs Aspirin alone, placebo, or oral anticoagulants…
Design
Review
Authors
Loading...
Highlights bleeding trade-offs with antiplatelets in stroke prevention; leaves open etiology-specific optimization.
What is the role of various antiplatelet agents and oral anticoagulants in the primary and secondary prevention of stroke across different patient populations?
This review summarizes the evidence for antiplatelet and anticoagulant therapies in stroke prevention, highlighting tailored approaches based on etiology such as atrial fibrillation versus non-cardioembolic stroke.
Weber et al. (2009) conducted a review in Stroke prevention. Antiplatelet agents was evaluated. Antiplatelet agents such as aspirin and clopidogrel reduce ischemic events in primary and secondary stroke prevention, though more potent regimens increase bleeding complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: